{"id":"flomoxef","rwe":[{"pmid":"41901599","year":"2026","title":"Evaluating the Risk of Coagulopathy in Cephalosporins with Different Side Chains: A Propensity Score-Weighted Study.","finding":"","journal":"Medicina (Kaunas, Lithuania)","studyType":"Clinical Study"},{"pmid":"41844876","year":"2026","title":"Analysis of perioperative antibiotic usage in the operating room during the 2019 cefazolin shortage in Japan: a multicenter observational study.","finding":"","journal":"Journal of anesthesia","studyType":"Clinical Study"},{"pmid":"41586323","year":"2026","title":"Association between antimicrobial use and the detection rates of carbapenem-resistant Enterobacterales: long-term surveillance results from a single centre.","finding":"","journal":"Infection prevention in practice","studyType":"Clinical Study"},{"pmid":"41459929","year":"2026","title":"Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1).","finding":"","journal":"Antimicrobial agents and chemotherapy","studyType":"Clinical Study"},{"pmid":"41161476","year":"2025","title":"Development of two methods for detecting Streptococcus mitis/oralis-related species with meropenem-non-susceptibility.","finding":"","journal":"Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy","studyType":"Clinical Study"}],"tags":[{"label":"flomoxef","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01DC14","category":"atc"},{"label":"Active","category":"status"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["flomoxef"],"offLabel":[],"synonyms":["flomoxef"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"flomoxef","explanation":"Imagine the bacterial cell wall as a brick wall. FLOMOXEF blocks the enzymes that help build the wall, causing the wall to weaken and eventually collapse. This prevents the bacteria from growing and multiplying, ultimately leading to the death of the bacterial cell.","oneSentence":"FLOMOXEF works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","technicalDetail":"FLOMOXEF exerts its antibacterial effect by inhibiting the activity of penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. This results in the accumulation of peptidoglycan precursors, leading to cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1179","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLOMOXEF","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLOMOXEF","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:29:01.841129","biosimilars":[],"competitors":[{"drugName":"cefoxitin","drugSlug":"cefoxitin","fdaApproval":"1978-10-18","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefuroxime","drugSlug":"cefuroxime","fdaApproval":"1983-10-19","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefaclor","drugSlug":"cefaclor","fdaApproval":"1979-04-04","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefotetan","drugSlug":"cefotetan","fdaApproval":"1985-12-27","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefonicid","drugSlug":"cefonicid","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefotiam","drugSlug":"cefotiam","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"loracarbef","drugSlug":"loracarbef","fdaApproval":"1991-12-31","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefmetazole","drugSlug":"cefmetazole","fdaApproval":"1989-12-11","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefprozil","drugSlug":"cefprozil","fdaApproval":"1991-12-23","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceforanide","drugSlug":"ceforanide","fdaApproval":"1984-05-24","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"flomoxef","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cefoxitin","brandName":"cefoxitin","genericName":"cefoxitin","approvalYear":"1978","relationship":"same-class"},{"drugId":"cefuroxime","brandName":"cefuroxime","genericName":"cefuroxime","approvalYear":"1983","relationship":"same-class"},{"drugId":"cefaclor","brandName":"cefaclor","genericName":"cefaclor","approvalYear":"1979","relationship":"same-class"},{"drugId":"cefotetan","brandName":"cefotetan","genericName":"cefotetan","approvalYear":"1985","relationship":"same-class"},{"drugId":"cefonicid","brandName":"cefonicid","genericName":"cefonicid","approvalYear":"","relationship":"same-class"},{"drugId":"cefotiam","brandName":"cefotiam","genericName":"cefotiam","approvalYear":"","relationship":"same-class"},{"drugId":"loracarbef","brandName":"loracarbef","genericName":"loracarbef","approvalYear":"1991","relationship":"same-class"},{"drugId":"cefmetazole","brandName":"cefmetazole","genericName":"cefmetazole","approvalYear":"1989","relationship":"same-class"},{"drugId":"cefprozil","brandName":"cefprozil","genericName":"cefprozil","approvalYear":"1991","relationship":"same-class"},{"drugId":"ceforanide","brandName":"ceforanide","genericName":"ceforanide","approvalYear":"1984","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02302092","phase":"PHASE3","title":"An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections","status":"TERMINATED","sponsor":"Takeda","startDate":"2015-12-01","conditions":["Urinary Tract Infection"],"enrollment":13,"completionDate":"2016-12-15"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"V9E5U5XF42","CHEBI":"CHEBI:135813","INN_ID":"5935","UMLSCUI":"C0117881","ChEMBL_ID":"CHEMBL15413","KEGG_DRUG":"D07963","DRUGBANK_ID":"DB11935","PUBCHEM_CID":"65864","IUPHAR_LIGAND_ID":"12251","MESH_SUPPLEMENTAL_RECORD_UI":"C045693"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.6 hours","clearance":"4.1 mL/min/kg","fractionUnbound":"0.64%","volumeOfDistribution":"0.19 L/kg"},"publicationCount":374,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DC14","allCodes":["J01DC14"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 11","pmid":"41901599","title":"Evaluating the Risk of Coagulopathy in Cephalosporins with Different Side Chains: A Propensity Score-Weighted Study.","journal":"Medicina (Kaunas, Lithuania)"},{"date":"2026 Mar 18","pmid":"41844876","title":"Analysis of perioperative antibiotic usage in the operating room during the 2019 cefazolin shortage in Japan: a multicenter observational study.","journal":"Journal of anesthesia"},{"date":"2026 Mar","pmid":"41586323","title":"Association between antimicrobial use and the detection rates of carbapenem-resistant Enterobacterales: long-term surveillance results from a single centre.","journal":"Infection prevention in practice"},{"date":"2026 Feb 4","pmid":"41459929","title":"Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1).","journal":"Antimicrobial agents and chemotherapy"},{"date":"2025 Dec","pmid":"41161476","title":"Development of two methods for detecting Streptococcus mitis/oralis-related species with meropenem-non-susceptibility.","journal":"Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","brandName":"FLOMOXEF","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FLOMOXEF is a small molecule antibiotic belonging to the flomoxef class. It is used to treat bacterial infections, although its specific indications are unknown. The commercial status of FLOMOXEF is unclear, as it is not stated whether it is patented or generic. Its half-life is approximately 0.6 hours, which may require frequent dosing. Further information on its approval status, bioavailability, and generic manufacturers is not available.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}